| Literature DB >> 32798764 |
Meghnad G Joshi1, Jeevitaa Kshersagar2, Shashikant R Desai3, Shimpa Sharma4.
Abstract
The current challenge of the COVID-19 pandemic is complicated by the limited therapeutic options against the virus, with many being anecdotal or still undergoing confirmatory trials, underlining the urgent need for novel strategies targeting the virus. The pulmotropic virus causes loss of oxygenation in severe cases with acute respiratory distress syndrome (ARDS) and need for mechanical ventilation. This work seeks to introduce placental extract-derived biologically active components as a therapeutic option and highlights their mechanism of action relevant to COVID-19 virus. Human placenta has been used in clinical practice for over a century and there is substantial experience in clinical applications of placental extract for different indications. Aqueous extract of human placentacontains growth factors, cytokines/chemokines, natural metabolic and other compounds, anti-oxidants, amino acids, vitamins, trace elements and biomolecules, which individually or in combination show accelerated cellular metabolism, immunomodulatory and anti-inflammatory effects, cellular proliferation and stimulation of tissue regeneration processes. Placental extract treatment is proposed as a suitable therapeutic approach consideringthe above properties which could protect against initial viral entry and acute inflammation of alveolar epithelial cells, reconstitute pulmonary microenvironment and regenerate the lung. We reviewed useful therapeutic information of placental biomolecules in relation to COVID-19 treatment. We propose the new approach of using placental growth factors, chemokines and cytokine which will execute antiviral activity in coordination with innate and humoral immunity and improve patient's immunological responses to COVID-19. Executing a clinical trial using placental extract as preventive, protective and/or therapeutic approach for COVID-19treatment could advance the development of a most promising therapeutic candidate that can join the armamentaria against the COVID-19 virus.Entities:
Keywords: Anti-inflammatory; Cellular proliferation; Immunomodulatory; Novel coronavirus COVID-19; Placental extract; Tissue regeneration
Mesh:
Substances:
Year: 2020 PMID: 32798764 PMCID: PMC7406421 DOI: 10.1016/j.placenta.2020.07.033
Source DB: PubMed Journal: Placenta ISSN: 0143-4004 Impact factor: 3.481
Fig. 1Schematic of the coronavirus.The viruses are pleomorphic spherical particles with bulbous surface projections (~80–90 nm). Viral particles enclose a positive single stranded RNA genome complexed with the basic nucleocapsid (N) phosphoprotein. The virus consists of a lipid bilayer that anchors the membrane (M), envelope (E) and spike (S) proteins. A subset of coronaviruses have a shorter spike-like surface protein called hemagglutinin esterase. Spike glycoprotein (S), the type I glycoprotein forms glycosylated peplomers giving it a crown-like morphology. It provides the virus its bulbous surface projections. It interacts with its compliment host cell receptor in determining the tissue tropism and infectivity. The membrane glycoprotein (M), is highly hydrophobic, and has a short N-terminal ectodomain and a cytoplasmic tail. It spans the membrane three times. Small Envelop Glycoprotein (E), a membrane-spanning protein, is a highly hydrophobic protein. It has a short ectodomain, a transmembrane domain, and a cytoplasmic tail. The lipid bilayer envelope, membrane glycoproteins, and nucleocapsid shield the virus when it is outside the host.
Fig. 2The Mechanism of human CoVID-19 infection: 1: infected animals can infect Humans followed by human-to-human transmission through aerial droplets and contact. 2: life cycle begins with S protein binds to the cellular receptor ACE2. After receptor binding, S protein facilitates viral envelope fusion with the cell membrane through the endosomal pathway. Then CoVID-19 releases RNA into the host cell. Viral genomic RNA is translated into viral replicase polyproteins, which are then cleaved into small viral proteases. The RNA polymerase generates a series of sub genomic mRNAs and finally translated into all viral proteins. Viral genome RNA and proteins are subsequently assembled into virions in the endoplasmic reticulum, then to Golgi and transported via vesicles and released out of the cell. 3: CoVID-19 infection results in activation of epithelial cells, macrophages and dendritic cells. Antigens will be presented to the antigen presentation cells (APC), which triggers body's anti-viral immunity and uncontrolled systemic inflammatory response resulting from the release of large amounts of pro-inflammatory cytokines (IFN-α, IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-33, TNF-α, TGFβ, etc.) and chemokines (CCL2, CCL3, CCL5, CXCL8, CXCL9, CXCL10, etc.) by immune effector cells. 4: The cytokine storm will trigger a violent attack of immune system to the body, results in leaky blood vessels, cellular oedema and collapsed alveolar function. 5: Increased amount of IL6 and IL-1β results in activation of prostaglandins which results in increased body temperature. 5: System inflammation leads to decreased blood volume and increased hat ? function. Finally, it results in multiple organ failure, and may lead to death in severe cases.
Fig. 4Functions of major cytokines and chemokines in placental extract.
Fig. 5Mechanism of Placental Extract mediated immunosurveillance.
Primers and probes, real-time RT-PCR for SARS-CoV-2 virus(42).
| Assay/use | Oligonucleotide | Sequence | Concentration |
|---|---|---|---|
| RdRP gene | RdRp_SARSr-P2 | FAM-CAGGTGGAACCTCATCAGGAGATGC-BBQ | Specific for 2019-nCoV, will not detect SARS-CoV. |
| Use 100 nM per reaction and mix with P1 | |||
| RdRP_SARSr-P1 | FAM-CCAGGTGGWACRTCATCMGGTGATGC-BBQ | Pan Sarbeco-Probe will detect 2019-nCoV, SARS-CoV and bat-SARS-related CoVs. | |
| Use 100 nM per reaction and mix with P2 | |||
| RdRp_SARSr-R | CARATGTTAAASACACTATTAGCATA | Use 800 nM per reaction | |
| E gene | E_Sarbeco_F | ACAGGTACGTTAATAGTTAATAGCGT | Use 400 nm per reaction |
| E_Sarbeco_P1 | FAM-ACACTAGCCATCCTTACTGCGCTTCG-BBQ | Use 200 nm per reaction | |
| E_Sarbeco_R | ATATTGCAGCAGTACGCACACA | Use 400 nm per reaction | |
| N gene | N_Sarbeco_F | CACATTGGCACCCGCAATC | Use 600 nm per reaction |
| N_Sarbeco_P | FAM-ACTTCCTCAAGGAACAACATTGCCA-BBQ | Use 200 nm per reaction | |
| N_Sarbeco_R | GAGGAACGAGAAGAGGCTTG | Use 800 nm per reaction |
W is A/T; R is G/A; M is A/C; S is G/C. FAM: 6-carboxyfluorescein; BBQ: blackberry quencher.
Optimised concentrations are given in nanomol per litre (nM) based on the final reaction mix, e.g. 1.5 μL of a 10 μM primer stock solution per 25 μL total reaction volume yields a final concentration of 600 nM as indicated in the table.
Fig. 3Biochemical composition of placenta.Therapeutic advantages of placental extract are attributed to their composition and properties. Different growth factors, cytokines/chemokines, metabolic and other trace elements, and natural antioxidants have anti-inflammatory, antibacterial, antiviral properties that are supportive of activation of monocytes and macrophages. These factors enhance the migration, proliferation and survival of macrophages and attracts monocytes and stimulates macrophages to release angiogenic and lymphangiogenic factors. Placental biochemical composition has direct consequence on the inflammatory reaction because, by binding to VEGF on monocytes, activates TNF-α and IL-6 production via a calcineurin-dependent pathway. These immunoglobulin therapies can assist to treat patients with the virus infection.
Potential role of placental growth factors in host defense.
| Sr. | Growth Factor | Potential Role |
|---|---|---|
| 1. | Hepatocyte Growth Factor (HGF) | *Essential for organ development and Self |
| Repair | ||
| *Prohibits apoptotic signals | ||
| *Inhibits neutrophil infiltration | ||
| *Angiogenic factor and anti-thrombosis | ||
| *prohibit viral replication | ||
| 2. | Nerve Growth Factor (NGF) | *Promotes the pathological neovascularization process. |
| *act as an indirect activator of endothelial cell growth by stimulating the release of other vascular growth factors. | ||
| *NGF stimulates the proliferation of B and T lymphocytes. | ||
| *nervous and immune systems collaborate in the control of homeostasis and host defence. | ||
| 3. | Epidermal Growth Factor (EGF) | *Airway epithelial surface: mucin production |
| and secretion. | ||
| *Neutrophil recruitment (via interleukin-8 | ||
| production) | ||
| *Important role in airway epithelial repair. | ||
| 4. | Fibroblast Growth Factor (FGF) | *Recruitment and activation of neutrophils. |
| *A potent mitogen for airway smooth muscle cells. | ||
| *Maintains the innate immune homeostasis of antiviral immunity by stabilizing retinoic acid- inducible gene-I (RIG-I) and preventing proteasome-mediated RIG-I degradation. | ||
| *Repair and maintenance of epithelial cells and epithelial integrity. | ||
| 5. | Insulin-like Growth Factor (IGF) | *Important role in the regulation of inflammation in the immune system. |
| *Important role in the process of cell growth, differentiation, and apoptosis. | ||
| 6. | Colony-Stimulating Factor (CSF) | *Promote differentiation, activation and mobilization of myeloid cells. |
| *Drives immune functions of alveolar macrophages and dendritic cells (DCs). | ||
| *Increases mono- nuclear phagocyte-mediated innate and adaptive host defence and accelerates epithelial repair. | ||
| 7. | Vascular Endothelial Growth Factor (VEGF) | *crucial roles in promoting cell proliferation, cell migration, increasing the vasopermeability, and promoting angiogenesis. |
| *Roles in recruitment of hematopoietic stem cells, migration of monocytes and macrophages. | ||
| *Participates in innate immunity and is responsive to pathogen infection. | ||
| *Inhibition of apoptosis, and virus infection. |